Phibro Animal Health (PAHC) Cash from Investing Activities (2013 - 2026)
Phibro Animal Health (PAHC) posted quarterly Cash from Investing Activities of -$16.8 million for Q1 2026, up 7.92% year-over-year from -$15.6 million in Q1 2025, and up 2.2% quarter-over-quarter from -$17.2 million in Q4 2025.
Phibro Animal Health (PAHC) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Phibro Animal Health's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$16.8 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 7.92% year-over-year to -$16.8 million; the TTM figure through Mar 2026 stood at -$62.0 million (up 78.66% YoY), while the FY2025 annual figure was -$288.7 million, down 499.01% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$16.8 million, up from -$17.2 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $1.1 million in Q1 2024, with the low at -$260.5 million in Q4 2024.
- The 5-year median for Cash from Investing Activities is -$15.4 million (2023), against an average of -$28.6 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities jumped 102.99% in 2024, then slumped 1715.13% in 2025.
- Phibro Animal Health's Cash from Investing Activities stood at -$9.8 million in 2022, then tumbled by 153.43% to -$24.9 million in 2023, then tumbled by 947.72% to -$260.5 million in 2024, then soared by 93.4% to -$17.2 million in 2025, then advanced by 2.2% to -$16.8 million in 2026.
- Business Quant data shows PAHC's Cash from Investing Activities at -$16.8 million in Q1 2026, -$17.2 million in Q4 2025, and -$21.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Phibro Animal Health | 1.42 Bn | 1.35 Bn | 125.68 Mn | -16.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.81 Mn |
| Mar 31, 2026 | -16.81 Mn |
| Dec 31, 2025 | -17.18 Mn |
| Dec 31, 2025 | -17.18 Mn |
| Sep 30, 2025 | -21.01 Mn |
| Sep 30, 2025 | -21.01 Mn |
| Jun 30, 2025 | -7.03 Mn |
| Jun 30, 2025 | -7.03 Mn |
| Mar 31, 2025 | -18.25 Mn |
| Mar 31, 2025 | -18.25 Mn |
| Dec 31, 2024 | -260.47 Mn |
| Dec 31, 2024 | -260.47 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | -9.11 Mn |
| Jun 30, 2024 | -9.11 Mn |
| Mar 31, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.13 Mn |
| Dec 31, 2023 | -24.86 Mn |
| Dec 31, 2023 | -24.86 Mn |